Table 2 Resource items for screening, diagnostics and treatment: unit prices for the Netherlands and the United Kingdom, and sources

From: Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness

Cost category

Unit price € (The Netherlands)

Source

Unit price £ (United Kingdom)

Source/HRG code

Screening

Mammography (National Breast Screening Program)

69

www.cvz.nl

46

www.whnt.nhs.uk

Mammography (hospital)

92

www.cvz.nl

58

NICE (2006)

MRI

227

www.cvz.nl

220

Prescott et al (2007)

Diagnostics

Pathology and evaluation

75

Flobbe et al (2004)

122

Prescott et al (2007)

Treatment

Breast conserving therapy

1009

www.cvz.nl

808

a

Mastectomy

1856

www.cvz.nl

2549

HRG J11

Radiation therapy

2891

Flobbe et al (2004); LPRM and NABON (2000); Slotman et al (2000)

2316

a

Chemo therapy

950

Flobbe et al (2004); Slotman et al (2000)

761

a

Hormonal therapy

733

Flobbe et al (2004); Slotman et al (2000)

587

a

Specialist visits

672

Flobbe et al (2004)

538

a

Specialist visits (adjuvant therapy)

1788

Flobbe et al (2004)

1433

a

Hospital stay

1594

Flobbe et al (2004); Oostenbrink et al (2000)

1277

a

  1. Abbreviation: HRG=Healthcare Research Group.
  2. aIf there was no HRG code, prices calculated were based on the balance between the per capita expenditures of the Netherlands vs that of the United Kingdom (0.84) (stats.oecd.org, visited online: June 2012) and the conversion rate on 1 January 2009, which is 0.96 for UK pounds (www.x-rates.com visited online: June 2012).